Date: 2014-01-20
Type of information: Distribution agreement
Compound: epigenetic proteins
Company: Cisbio Bioassays (France) Reaction Biology (USA)
Therapeutic area: Technology - Services
Type agreement: distribution
Action mechanism:
Disease:
Details: * On January 20, 2014, Reaction Biology Corporation, a contract research organization providing early stage drug discovery services, has announced that it has signed an agreement for Cisbio Bioassays, a biotechnology company in the field of products and services for human in vitro diagnostics and pharmaceutical research, to distribute its epigenetic proteins. RBC manufactures one of the largest collections of recombinant human epigenetic proteins. These proteins modulate genetic function in humans and are the subject of intense research in the pharmaceutical industry to validate them as targets for a new generation of cancer drugs. Cisbio
develops and markets a broad selection of assays used worldwide by researchers in drug discovery. The company has recently expanded its product offering with very innovative solutions to assess epigenetic targets such as methyltransferases. The new agreement will give Cisbio worldwide rights to co-market and sell RBC’s proteins.
Financial terms:
Latest news:
